A and R Health Services INC.

A and R Health Services INC. was paid $1.54M by Medicaid between Feb 2020 and Aug 2024, across 7 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 42% of everything it billed.

Compared with peers

Next to other Addiction (Substance Use Disorder) Counselor providers in Pennsylvania

Rank by total paid#26 of 83

Median peer was paid$213K

This provider vs. median7.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	3,390	$180K
2021	9,455	$383K
2022	10,245	$459K
2023	9,829	$381K
2024incomplete	2,555	$138K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	42%	7,907	4,439	$645K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	41%	14,865	7,629	$630K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	13%	6,256	3,480	$200K
80305		2.8%	5,453	3,163	$42K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	1.3%	956	636	$21K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	24	24	$2K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	<1%	13	13	$379.75

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialROSCOE, GREGORY (EXECUTIVE DIRECTOR)

Same official

Other billing entities under ROSCOE, GREGORY

Full network →

Provider	Location	Paid
Curo Aegar Recovery Education INC	West Chester, PA	$1.51M
Clearfield Jefferson Head and Neck Surgical Associates, INC.	Du Bois, PA	$85K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.